echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Microbiology News > Diagnosis of Parvovirus B19-DNA by Dot-Blot Hybridization

    Diagnosis of Parvovirus B19-DNA by Dot-Blot Hybridization

    • Last Update: 2021-02-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Parvovirus B 19 was discovered at the Virus Reference Laboratory in 1975 by Cossart and colleagues (
    1
    ). First found in healthy blood donors, parvovirus B19 infection usually manifests as erythema infectiosum (fifth disease) in children. In adults the infection can cause acute arthritis. The virus replicates in erythroid progenitors, and patients with an underlying hemolytic anemia can experience a transient aplastic crisis. Anaemia may occur in immunocompromised patients due to persistent B19 infection and this can be treated with immunoglobulin. Infection during pregnancy can result in fetal anemia, hydrops fetalis, and intrauterine death.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.